相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia
Melissa M. Berrien-Elliott et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Role of IL-10-Producing Natural Killer Cells in the Regulatory Mechanisms of Inflammation during Systemic Infection
Israel Martinez-Espinosa et al.
BIOMOLECULES (2022)
The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation
Maria L. Amaya et al.
BLOOD (2022)
Signal transducer and activator of transcription 3 signaling in tumor immune evasion
Luying Zhang et al.
PHARMACOLOGY & THERAPEUTICS (2022)
Combination Blockade of the IL6R/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells
S. Gonzalez-Ochoa et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2022)
Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
Alessandro Poggi et al.
MOLECULAR THERAPY-ONCOLYTICS (2022)
Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells
Cedric Pastoret et al.
BLOOD (2021)
The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy
Manlio Tolomeo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
STAT3 plays an important role in DNA replication by turning on WDHD1
Yunying Zhou et al.
CELL AND BIOSCIENCE (2021)
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma
Junnv Xu et al.
FRONTIERS IN ONCOLOGY (2021)
STAT3 governs the HIF-1α response in IL-15 primed human NK cells
Anna Coulibaly et al.
SCIENTIFIC REPORTS (2021)
Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma
Lili Huang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotype
Laura Faletti et al.
BIOMEDICAL JOURNAL (2021)
STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation
Daehong Kim et al.
LEUKEMIA (2021)
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klara Klein et al.
CANCERS (2021)
The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
Bernhard Moser et al.
BIOMEDICINES (2021)
The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients
Gregorio Barila et al.
LEUKEMIA (2020)
Distinct molecular response patterns of activating STAT3 mutations associate with penetrance of lymphoproliferation and autoimmunity
Sabine Jaegle et al.
CLINICAL IMMUNOLOGY (2020)
CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
Shi Yong Neo et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells
Genki Okumura et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition
Wook Jin
CELLS (2020)
Immune escape and immunotherapy of acute myeloid leukemia
Luca Vago et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Programmed cell death protein 1 on natural killer cells: fact or fiction?
Monica M. Cho et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Minimal PD-1 expression in mouse and human NK cells under diverse conditions
Sean J. Judge et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells
Vanessa Rebecca Gasparini et al.
BLOOD CANCER JOURNAL (2020)
Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways
Rui Teng et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
Targeting STAT3 and STAT5 in Cancer
Elvin D. de Araujo et al.
CANCERS (2020)
Targeting STAT3 in Cancer Immunotherapy
Sailan Zou et al.
MOLECULAR CANCER (2020)
STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity
Katrin Meissl et al.
FRONTIERS IN IMMUNOLOGY (2020)
The cancer-natural killer cell immunity cycle
Nicholas D. Huntington et al.
NATURE REVIEWS CANCER (2020)
STAT3 isoforms: Alternative fates in cancer?
Petra Aigner et al.
CYTOKINE (2019)
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Simona Sivori et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
STAT3 mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells
Toru Kawakami et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
STAT3beta, a distinct isoform from STAT3
Hui-Xiang Zhang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2019)
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Jiang-Jiang Qin et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
STAT3 directly regulates NKp46 transcription in NK cells of HBeAg-negative CHB patients
Bingqing Zheng et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
Rapamycin downregulates NKG2D ligands in acute myeloid leukemia cells via an activation of the STAT3 pathway: a potential mechanism for rapamycin-induced immune escape in leukemia
Zhichao Zhu et al.
TRANSLATIONAL CANCER RESEARCH (2019)
T cell large granular lymphocyte leukemia and chronic NK lymphocytosis
Gregorio Barila et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma
Jian Wu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
The Natural Cytotoxicity Receptors in Health and Disease
Alexander David Barrow et al.
FRONTIERS IN IMMUNOLOGY (2019)
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
Fan Luo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Interleukin-15 Signaling in HIF-1α Regulation in Natural Killer Cells, Insights Through Mathematical Models
Anna Coulibaly et al.
FRONTIERS IN IMMUNOLOGY (2019)
JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation
Dagmar Gotthardt et al.
FRONTIERS IN IMMUNOLOGY (2019)
STAT3 Dysregulation in Mature T and NK Cell Lymphomas
Angelina Seffens et al.
CANCERS (2019)
Structural Implications of STAT3 and STAT5 SH2 Domain Mutations
Elvin D. de Araujo et al.
CANCERS (2019)
Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map
Jennifer Huynh et al.
NATURE REVIEWS CANCER (2019)
HIF-1α induces immune escape of prostate cancer by regulating NCR1/NKp46 signaling through miR-224
Chao-hao Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari et al.
BLOOD (2018)
IL-10+ NK and TGF-β+ NK cells play negative regulatory roles in HIV infection
Yongjun Jiang et al.
BMC INFECTIOUS DISEASES (2018)
Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer
Antonino Bruno et al.
FASEB JOURNAL (2018)
Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer
Bettina Wingelhofer et al.
LEUKEMIA (2018)
Combined inhibition of JAK1,2/Stat3-PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia
Li-Jun Xu et al.
MOLECULAR MEDICINE REPORTS (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Jenny D. Beebe et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
Olli Dufva et al.
NATURE COMMUNICATIONS (2018)
Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation
Gregorio Barila et al.
BLOOD CANCER JOURNAL (2018)
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Tammy Linlin Song et al.
BLOOD (2018)
PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients
Fernando Concha-Benavente et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Simon A. Jones et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy
Sara Mastaglio et al.
BLOOD ADVANCES (2018)
Disruption of SOCS3 Promotes the Anti-Cancer Efficacy of Primary NK Cells
Meisam Naeimi Kararoudi et al.
BLOOD (2018)
Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia
Liang Huang et al.
CELL RESEARCH (2018)
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Derek J. Jonker et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases
Tiziana Lorenzini et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
The Broad Spectrum of Human Natural Killer Cell Diversity
Aharon G. Freud et al.
IMMUNITY (2017)
STAT3 inhibition by STA21 increases cell surface expression of MICB and the release of soluble MICB by gastric adenocarcinoma cells
Macarena Garrido-Tapia et al.
IMMUNOBIOLOGY (2017)
Tricking the balance: NK cells in anti-cancer immunity
Jens Pahl et al.
IMMUNOBIOLOGY (2017)
Subset-and tissue-defined STAT5 thresholds control homeostasis and function of innate lymphoid cells
Alejandro V. Villarino et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
V. Atsaves et al.
LEUKEMIA (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Developmental and Functional Control of Natural Killer Cells by Cytokines
Yang Wu et al.
FRONTIERS IN IMMUNOLOGY (2017)
STATs in NK-Cells: The Good, the Bad, and the Ugly
Dagmar Gotthardt et al.
FRONTIERS IN IMMUNOLOGY (2017)
Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors
Lisa N. Heppler et al.
TRENDS IN CANCER (2017)
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Yulong Gao et al.
NATURE IMMUNOLOGY (2017)
STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds
Schafiq Nabhani et al.
CLINICAL IMMUNOLOGY (2017)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Elucidating the effects of disease-causing mutations on STAT3 function in autosomal-dominant hyper-IgE syndrome
Simon J. Pelham et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion
Dagmar Gotthardt et al.
CANCER DISCOVERY (2016)
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Asma Beldi-Ferchiou et al.
ONCOTARGET (2016)
Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma
Uddalak Bharadwaj et al.
ONCOTARGET (2016)
Regulation of Natural Killer Cell Function by STAT3
Nicholas A. Cacalano
FRONTIERS IN IMMUNOLOGY (2016)
Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing
Conor J. Kearney et al.
ONCOIMMUNOLOGY (2016)
STAT3: too much may be worse than not enough!
Elie Haddad
BLOOD (2015)
Strategy of STAT3β cell-specific expression in macrophages exhibits antitumor effects on mouse breast cancer
W. Dang et al.
GENE THERAPY (2015)
STAT3 contributes to NK cell recognition by modulating expression of NKG2D ligands in adriamycin-resistant K562/AO2 cells
Xiaohui Cai et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David Hong et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
Can Kucuk et al.
NATURE COMMUNICATIONS (2015)
Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type
Seungbok Lee et al.
ONCOTARGET (2015)
Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3
Emma M. Haapaniemi et al.
BLOOD (2015)
Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations
Joshua D. Milner et al.
BLOOD (2015)
Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation
Shiguo Zhu et al.
BLOOD (2014)
Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance
Dagmar Gotthardt et al.
BLOOD (2014)
Mechanisms of Hypoxia-Mediated Immune Escape in Cancer
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations
Haoyu Sun et al.
CYTOKINE (2014)
A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis
Antonino Bruno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease
Sarah E. Flanagan et al.
NATURE GENETICS (2014)
Inhibition of IL-6 family cytokines by SOCS3
Jeffrey J. Babon et al.
SEMINARS IN IMMUNOLOGY (2014)
Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance
Eva Maria Putz et al.
CANCERS (2014)
Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia
Antonella Teramo et al.
BLOOD (2013)
Epithelial-Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor
Alejandro Lopez-Soto et al.
JOURNAL OF IMMUNOLOGY (2013)
Inhibition of Glycogen Synthase Kinase-3 Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of STAT3
Cinzia Fionda et al.
JOURNAL OF IMMUNOLOGY (2013)
STAT5 Outcompetes STAT3 To Regulate the Expression of the Oncogenic Transcriptional Modulator BCL6
Sarah R. Walker et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions via Reverse Hepatocellular Carcinoma-Induced Immune Suppression
Xiaoxia Sun et al.
MOLECULAR CANCER THERAPEUTICS (2013)
STAT3 mutations are highly specific for large granular lymphocytic leukemia
A. Fasan et al.
LEUKEMIA (2013)
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection
Joachim Koch et al.
TRENDS IN IMMUNOLOGY (2013)
Tumor-primed NK cells: waiting for the green light
May Sabry et al.
FRONTIERS IN IMMUNOLOGY (2013)
The Proangiogenic Phenotype of Natural Killer Cells in Patients with Non-Small Cell Lung Cancer
Antonino Bruno et al.
NEOPLASIA (2013)
STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia
Andres Jerez et al.
BLOOD (2012)
Inhibitory Roles of Signal Transducer and Activator of Transcription 3 in Antitumor Immunity during Carcinogen-Induced Lung Tumorigenesis
Shoichi Ihara et al.
CANCER RESEARCH (2012)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman et al.
PLOS ONE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development
Eva Eckelhart et al.
BLOOD (2011)
Novel Role for STAT3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells
Romain Bedel et al.
CANCER RESEARCH (2011)
Dynamics of the STAT3 Transcription Factor: Nuclear Import Dependent on Ran and Importin-β1
Velasco Cimica et al.
PLOS ONE (2011)
Antitumorigenic potential of STAT3 alternative splicing modulation
Francesca Zammarchi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Innate or Adaptive Immunity? The Example of Natural Killer Cells
Eric Vivier et al.
SCIENCE (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Stat3 Is a Negative Regulator of Intestinal Tumor Progression in ApcMin Mice
Monica Musteanu et al.
GASTROENTEROLOGY (2010)
Interleukin-27 Activates Natural Killer Cells and Suppresses NK-Resistant Head and Neck Squamous Cell Carcinoma through Inducing Antibody-Dependent Cellular Cytotoxicity
Masahiro Matsui et al.
CANCER RESEARCH (2009)
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
Cameron S. Brandt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma
P. Coppo et al.
LEUKEMIA (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Function of Mitochondrial Stat3 in Cellular Respiration
Joanna Wegrzyn et al.
SCIENCE (2009)
Oncogenic stress sensed by the immune system: role of natural killer cell receptors
David H. Raulet et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Role of Stat3 in suppressing anti-tumor immunity
Marcin Kortylewski et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Nadia Guerra et al.
IMMUNITY (2008)
Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D
Akio Takada et al.
JOURNAL OF IMMUNOLOGY (2008)
Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1α RNA expression in both tumor cells and tumor-associated myeloid cells
Guilian Niu et al.
MOLECULAR CANCER RESEARCH (2008)
Natural killer cell recognition of missing self
Klas Karre
NATURE IMMUNOLOGY (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Interleukin-21 differentially affects human natural killer cell subsets
Katy Wendt et al.
IMMUNOLOGY (2007)
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Hua Yu et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Self-tolerance of natural killer cells
David H. Raulet et al.
NATURE REVIEWS IMMUNOLOGY (2006)
The comparative roles of suppressor of cytokine signaling-1 and-3 in the inhibition and desensitization of cytokine signaling
S Wormald et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
IL-21 down-regulates NKG2D/DAP10 express on human NK and CD8+ T cells
SJ Burgess et al.
JOURNAL OF IMMUNOLOGY (2006)
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
M Kortylewski et al.
NATURE MEDICINE (2005)
IL-21 enhances tumor rejection through a NKG2D-dependent mechanism
R Takaki et al.
JOURNAL OF IMMUNOLOGY (2005)
Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias
P Nowbakht et al.
BLOOD (2005)
The STAT3 isoforms and have unique and specific functions
D Maritano et al.
NATURE IMMUNOLOGY (2004)
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
TH Wang et al.
NATURE MEDICINE (2004)
GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor
C Diveu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Roles of the NKG2D immunoreceptor and its ligands
DH Raulet
NATURE REVIEWS IMMUNOLOGY (2003)
Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule
C Bottino et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially cytokine signaling 3
C Niemand et al.
JOURNAL OF IMMUNOLOGY (2003)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
A Diefenbach et al.
NATURE (2001)
Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
PK Epling-Burnette et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
D Cosman et al.
IMMUNITY (2001)
Serine phosphorylation of STATs
T Decker et al.
ONCOGENE (2000)
分享论文
